Corporate Profile

We are a clinical-stage liver therapeutics company pioneering a new class of medicines designed to bring safe and efficacious fibrosis and cancer treatments to patients.

By employing our world-leading expertise in galectin and LOXL2 biology, we have developed our lead product candidates to modulate multiple disease pathways simultaneously and work synergistically with and enhance the efficacy of other therapeutics.

Our research indicates galectin-3 and LOXL2 are implicated in disease progression and may also be pivotal to new therapeutic strategies. These proteins play significant roles in inflammation, fibrosis, and the development and progression of cancer, making them promising targets for effective treatments.

Our efforts to date have already begun to show potential. For example, our small molecule galectin-3 inhibitor, GB1211, has shown preclinical promise in reversing galectin-3-induced resistance to checkpoint inhibitors. We anticipate that our concentrated efforts will lead to new advancements in the management of HCC, BTC, liver fibrosis, and cirrhosis, providing patients with more options and better outcomes. We announced topline results from our Phase 1b/2a GULLIVER-2 study which showed statistically significant reductions in liver enzymes and other positive biomarker effects after up to 12 weeks of treatment in [42] patients.

Galecto’s increased focus on liver diseases is an exciting chapter in our company’s evolution. As we deepen our understanding of these diseases, we’re poised to make significant strides in the development of novel therapies. This focus underscores our commitment to transforming patients’ lives by providing innovative solutions to complex medical challenges.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

01 May '24
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and
21 Dec '23
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target BOSTON , Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc.
23 Oct '23
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks BOSTON , Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development